Financial Performance - The company reported a total revenue of RMB 90.6 million for the year ending December 31, 2025, with other income and gains amounting to RMB 16.6 million, totaling RMB 107.2 million[3]. - The adjusted loss for the year, excluding share-based payment expenses and foreign exchange fluctuations, was RMB 162.4 million, a decrease of 11.3% compared to RMB 183.0 million in the previous year[4]. - The net cash flow used in operating activities was RMB 75.0 million, a significant decline of 65.5% from RMB 217.6 million in the previous year[4]. - The net loss for the year was RMB 272,704 thousand, compared to a loss of RMB 185,829 thousand in the previous year[18]. - The company reported a net loss attributable to equity holders of the parent of RMB 271,229,000 for the year ended December 31, 2025, compared to a loss of RMB 177,510,000 in 2024, representing an increase in loss of approximately 53%[19]. - The basic and diluted loss per share for the year was RMB 0.64, compared to RMB 0.43 in the previous year, indicating a worsening of the loss per share by approximately 49%[19]. - The group reported a pre-tax loss of RMB 78,762,000 for 2025, compared to RMB 70,318,000 in 2024[34]. - Research and development expenses increased to RMB 183,609,000 in 2025, up from RMB 142,637,000 in 2024[34]. - The financing cost increased from RMB 289,000 as of December 31, 2024, to RMB 867,000 during the reporting period, primarily due to rising interest rates on bank and other loans[93]. - The adjusted net loss under non-IFRS measures for 2025 is RMB 162.4 million, compared to RMB 183.0 million for 2024[96]. Product Development and Commercialization - The company is focusing on the commercialization of structural heart disease intervention products, with a strong emphasis on international expansion and the transformation of core technological achievements into market value[5]. - The LuX-Valve Plus product has accelerated its global clinical registration process, with successful FDA IDE approval for pivotal trials in the U.S. and ongoing CE certification in Europe[6]. - Ken-Valve has established a comprehensive sales network across hundreds of hospitals in China, achieving rapid sales and implantation growth in its first year of commercialization[9]. - The company aims to maintain its leading advantage in the tricuspid valve intervention field and advance the commercialization of core products in various regions[8]. - Ken-Valve successfully entered the overseas mature market after receiving approval from New Zealand's Medsafe in February 2026, marking a key breakthrough in its globalization strategy[10]. - The company is focused on continuous innovation and R&D to optimize its core product matrix, enhancing operational efficiency for global development[16]. - The company is focused on developing products for structural heart disease interventions, with a commitment to international expansion and a diverse product pipeline[44]. - The company has multiple products at various stages of commercialization and development, including those approved in China and New Zealand[45]. - The company has submitted applications for regulatory approvals, including CE certification and registration with the National Medical Products Administration in China[45]. - The company has established a comprehensive regional distribution network for the Ken-Valve product line, covering procurement platforms in 30 provinces in China[76]. Clinical Studies and Results - The TRINITY clinical study results, demonstrating the safety and efficacy of LuX-Valve Plus, will be presented at major international conferences, further supporting the company's position in the tricuspid valve replacement therapy field[7]. - Clinical data from JensClip demonstrated significant improvements in safety and efficacy, gaining widespread attention from global clinical experts[14]. - The TRINITY study included 161 patients across 20 global centers, demonstrating positive safety and clinical performance for LuX-Valve Plus in high-risk patients[53]. - The TRINITY study's 6-month follow-up results indicate a composite adverse event rate of 19.9% and 94.4% of patients showing no moderate or severe regurgitation[55]. - In the TRINITY study, over 75% of patients used valve sizes of 55mm to 70mm, with a significant improvement in heart function and quality of life observed[56]. - Ken-Valve has achieved a 97.18% device success rate with an average operation time of 8.70 minutes, and a one-year all-cause mortality rate of only 5.63%[61]. - JensClip's clinical study showed a device operation success rate of approximately 95% and an all-cause mortality rate of only 1.8% after one year of follow-up[66]. Financial Position and Assets - Total non-current assets decreased to RMB 275,623,000 in 2025 from RMB 341,710,000 in 2024, reflecting a decline of about 19%[20]. - Current assets also decreased to RMB 620,609,000 in 2025 from RMB 685,855,000 in 2024, a reduction of approximately 9.5%[20]. - The company's total liabilities increased, with current liabilities rising to RMB 105,871,000 in 2025 from RMB 64,201,000 in 2024, an increase of about 65%[20]. - The company's total equity decreased to RMB 773,126,000 in 2025 from RMB 916,953,000 in 2024, a decline of approximately 16%[21]. - The company reported an increase in trade payables to RMB 25,150,000 in 2025 from RMB 12,097,000 in 2024, which is an increase of about 108%[20]. - Cash and cash equivalents decreased by 16.3% from RMB 606.0 million as of December 31, 2024, to RMB 507.4 million as of December 31, 2025[98]. - The current ratio decreased from 10.7 in 2024 to 5.9 in 2025, while the debt-to-asset ratio increased from 10.8% to 13.7%[101]. - The total amount of bank and other borrowings decreased from RMB 60.3 million as of December 31, 2024, to RMB 43.8 million as of December 31, 2025[101]. Governance and Compliance - The company has adopted the corporate governance code and has complied with all applicable provisions, except for a specific deviation regarding the roles of the chairman and CEO[118][119]. - The chairman and CEO roles were separated on January 15, 2025, to enhance corporate governance compliance[120]. - The audit committee, consisting of three independent non-executive directors, has reviewed the annual performance and confirmed compliance with applicable accounting standards[124][125]. - The company has received confirmation from all directors regarding compliance with the standard code of conduct for securities trading during the reporting period[122]. Employee and Shareholder Matters - The company has established a performance evaluation mechanism to assess employee performance, which influences salary adjustments and career development planning[109]. - The company adopted an employee incentive plan on October 30, 2020, and an H-share plan on December 15, 2023[110]. - The board of directors does not recommend the payment of a final dividend for the reporting period[114]. - The annual general meeting is scheduled for May 28, 2026, with a suspension of share transfer registration from May 22 to May 28, 2026[116][117].
健世科技(09877) - 2025 - 年度业绩